



IX BIOPHARMA LTD.

(Incorporated in the Republic of Singapore on 8 May 2004)
(Company Registration No. 200405621W)

Unless otherwise defined, all capitalised terms used herein shall bear the same meaning as used in the circular dated 1 October 2024 issued by iX Biopharma Ltd. (the "Circular").

NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting of iX Biopharma Ltd. ("**Company**") will be held at 2 Science Park Drive, Ascent Main Lobby, The Metro, Singapore 118222 on Thursday, 17 October 2024 at 11.00 a.m. (or as soon as practicable immediately following the conclusion or adjournment of the 2024 AGM to be held at 10.00 a.m. on the same day and at the same place) for the purpose of considering and, if thought fit, passing with or without modifications, the following Ordinary Resolutions:

RESOLUTION 1: ORDINARY RESOLUTION

TO APPROVE THE PROPOSED EXTENSION OF THE iX EMPLOYEE SHARE OPTION SCHEME

That:

- (a) pursuant to Rule 17.1 of the Rules of iX ESOS, the extension of the duration of the iX ESOS for a further period of 10 years from 17 June 2025 up to 16 June 2035 (both dates inclusive) be and is hereby approved;
- (b) the Rules of the iX ESOS (as proposed to be extended and altered) as set out in the Appendix A to the Company's Circular, incorporating the alterations to the Rules of the iX ESOS as described in the Circular, be and are hereby approved and adopted in substitution for, and to the exclusion of, the existing Rules of the iX ESOS; and
- (c) the Directors of the Company be and are hereby authorised:
 - (i) to administer the iX ESOS (as proposed to be extended and altered);
 - (ii) to modify and/or amend the iX ESOS from time to time provided that such modifications and/or alteration is effected in accordance with the provisions of the iX ESOS and to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the iX ESOS;
 - (iii) to offer and grant Option(s) in accordance with the Rules of the iX ESOS and to allot and issue and/or transfer from time to time such number of Shares as may be required to be allotted and issued and/or transferred pursuant to the exercise of the Options under the iX ESOS, provided that the number of Shares issued and issuable under the iX ESOS, the iX PSP and all outstanding options or awards granted under such other share-based incentive schemes of the Company shall not exceed 15.0% of the Company's total number of issued Shares (excluding treasury shares and subsidiary holdings); and
 - (iv) to complete and do all such acts and things (including executing such documents as may be required) as they may consider necessary, expedient or desirable to give effect to the transactions contemplated and authorised by this Ordinary Resolution 1 if they think fit and in the interests of the Company.

RESOLUTION 2: ORDINARY RESOLUTION

TO APPROVE THE PROPOSED EXTENSION OF THE iX PERFORMANCE SHARE PLAN

That:

- (a) pursuant to Rule 15.1 of the Rules of iX PSP, the extension of the duration of the iX PSP for a further period of 10 years from 17 June 2025 up to 16 June 2035 (both dates inclusive) be and is hereby approved;

- (b) the Rules of the iX PSP (as proposed to be extended and altered) as set out in the Appendix B to the Company's Circular, incorporating the alterations to the Rules of the iX PSP as described in the Circular, be and are hereby approved and adopted in substitution for, and to the exclusion of, the existing Rules of the iX PSP; and
- (c) the Directors of the Company be and are hereby authorised:
- (i) to administer the iX PSP (as proposed to be extended and altered);
 - (ii) to modify and/or amend the iX PSP from time to time provided that such modifications and/or alteration is effected in accordance with the provisions of the iX PSP and to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the iX PSP;
 - (iii) to offer and grant Award(s) in accordance with the Rules of the iX PSP and to allot and issue and/or transfer from time to time such number of Shares as may be required to be allotted and issued and/or transferred pursuant to the exercise of the Awards under the iX PSP, provided that the number of Shares issued and issuable under the iX PSP, the iX ESOS and all outstanding options or awards granted under such other share-based incentive schemes of the Company shall not exceed 15.0% of the Company's total number of issued Shares (excluding treasury shares and subsidiary holdings); and
 - (iv) to complete and do all such acts and things (including executing such documents as may be required) as they may consider necessary, expedient or desirable to give effect to the transactions contemplated and authorised by this Ordinary Resolution 2 if they think fit and in the interests of the Company.

RESOLUTION 3: ORDINARY RESOLUTION

TO APPROVE THE PROPOSED PARTICIPATION OF MR. EDDY LEE YIP HANG IN THE EXTENDED iX PSP

That subject to and contingent upon Ordinary Resolution 2 being passed, approval be and is hereby given for the participation of Mr. Eddy Lee Yip Hang (who is regarded as a Controlling Shareholder) in the extended iX PSP.

BY ORDER OF THE BOARD

Gwendolin Lee Soo Fern/Lai Kuan Loong, Victor
Company Secretaries
1 October 2024

Other Important Notes:

- (1) The Company's Notice of EGM, Circular dated 1 October 2024 and the accompanying proxy form ("**Proxy Form**") will be published on the Company's website at <https://www.ixbiopharma.com/newsroom/> or the SGX website at <https://www.sgx.com/securities/company-announcements>. Printed copies of this Notice of EGM and the accompanying Proxy Form will be sent to members by post.

Printed copies of the Circular will not be sent to members. A member may request for a printed copy of the Circular at the Company's principal place of business during office hours (Monday - Friday, 9.00 a.m - 5.30 p.m.), at 1 Kim Seng Promenade #14-01 Great World City East Lobby Singapore 237994 no later than 5.30 p.m. on 10 October 2024.

- (2) Members (whether corporate or individual) may vote in person at the EGM or appoint a proxy, including the Chairman of the EGM, to attend, speak and vote on his/her/its behalf at the EGM. Where no specific voting direction is given to the proxy/ proxies, the proxy/proxies will vote or abstain from voting at his/her/their discretion, on any matter arising at the EGM and at any adjournment thereof. Only members of the Company or their appointed proxy(ies) whose identities have been duly verified will be entitled to attend the EGM.
- (3) A member who is not a Relevant Intermediary is entitled to appoint up to two (2) proxies to attend, speak and vote at the EGM. Where such member appoints two (2) proxies, he/she should specify the proportion of his/her shareholding (expressed as a percentage of the whole) to be presented by each proxy in the Proxy Form. If no such proportion or number is specified, the first named proxy shall be deemed to represent 100% of his/her shareholding and the second named proxy shall be deemed to be an alternate to the first named.

"Relevant Intermediary" has the meaning ascribed to it in Section 181 of the Companies Act 1967 (the "**Companies Act**").

A member who is a Relevant Intermediary is entitled to appoint more than two (2) proxies to attend, speak and vote at the EGM, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member appoints more than two (2) proxies, the number of shares in relation to which each proxy has been appointed shall be specified in the Proxy Form. A proxy need not be a member of the Company.

- (4) The Proxy Form must be under the hand of the appointor or by his/her attorney duly authorised in writing. Where the Proxy Form is executed by a corporation, it must be executed as a deed in accordance with the Companies Act or under the hand of an attorney or an officer duly authorised, or in some other manner approved by the directors. Where the Proxy Form is executed by an attorney on behalf of the appointor, the letter or power of attorney or a duly certified copy thereof must be lodged at the Company's Shares Registrar, Tricor Barbinder Share Registration Services, at 9 Raffles Place, #26-01 Republic Plaza Tower I, Singapore 048619.
- (5) The Proxy Form must be submitted to the Company in the following manner:
 - (a) if submitted personally or by post, be lodged with the Company's Share Registrar, Tricor Barbinder Share Registration Services at 9 Raffles Place, #26-01 Republic Plaza Tower I, Singapore 048619; or
 - (b) if submitted electronically, be submitted via email to the Company at agm@ixbiopharma.com,and in each case, must be lodged and received (as the case may be) not less than seventy-two (72) hours before the time appointed for the EGM (i.e. by 11.00 a.m. on 14 October 2024).

- (6) An investor who buys shares using CPF monies and/or SRS monies ("**CPF and SRS Investor**") (as may be applicable) may attend and cast his/her vote(s) at the EGM in person. CPF and SRS Investors who are unable to attend the EGM but would like to vote, may inform their CPF and/or SRS Approved Nominees (CPF agent banks or SRS operators) to appoint the Chairman of the EGM to act as their proxy, in which case, the CPF and SRS Investors shall be precluded from attending the EGM.
- (7) CPF and SRS Investors who wish to exercise their voting rights at the EGM should approach the CPF Agent bank or SRS operators (as the case may be) to submit their votes at least seven (7) working days before the EGM (i.e. by 5.00 p.m. on 7 October 2024) in order to allow sufficient time for their respective relevant intermediaries to submit the Proxy Form to vote on their behalf by the cut-off date. CPF Investors and SRS Investors should not directly appoint the Chairman as proxy to direct the vote.
- (8) All questions from members may be submitted in advance of the EGM, by no later than 10 a.m. on 8 October 2024 (i.e. seven (7) calendar days from the publication of the Notice of EGM), either (a) in hard copy by sending personally or by post at the Company's principal place of business at 1 Kim Seng Promenade, #14-01, Great World City East Lobby, Singapore 237994; (b) or electronically, via email to the Company at agm@ixbiopharma.com.

- (9) Members submitting questions are required to provide their particulars as follows:
- (a) Full name (for individuals) or company name (for corporates) as per CDP/SRS account records;
 - (b) National Registration Identity Card Number or Passport Number (for individuals) / Company Registration Number (for corporates);
 - (c) Number of shares held in the capital of the Company;
 - (d) Contact Number; and
 - (e) Email Address.
- (10) Members are strongly encouraged to submit questions and Proxy Forms electronically, via email.
- (11) The Management and Board of Directors of the Company will endeavour to address all substantial and relevant questions received from members by 11.00 a.m. on 12 October 2024 (i.e. 48 hours prior to the closing date and time for the lodgement of the proxy forms). The Company's responses to questions raised by members shall be published on the Company's website at <https://www.ixbiopharma.com/newsroom/> or the SGX website at <https://www.sgx.com/securities/company-announcements>.

PERSONAL DATA PRIVACY:

By submitting a Proxy Form appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the EGM and/or any adjournment thereof, a member of the Company consents to the collection, use and disclosure of the member's personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of proxies and representatives appointed for the EGM (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the EGM (including any adjournment thereof), and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines.
